France Drug Patents

« Back to Dashboard

Drug Patents in France and US Equivalents

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

Patent Number	Estimated Expiration	Equivalent US Patent	US Expiry Date	Generic Name	US Applicant	US Tradename
2282892		4199574	1997-04-22	acyclovir	Pharmobedient	ZOVIRAX
2342972		4199574	1997-04-22	acyclovir	Pharmobedient	ZOVIRAX
2837101		7579377	2025-02-23	adapalene	Galderma Labs Lp	DIFFERIN
2837101		7737181	2024-08-29	adapalene	Galderma Labs Lp	DIFFERIN
2837101		7834060	2023-03-12	adapalene	Galderma Labs Lp	DIFFERIN

Summary:
French patent law offers a well-defined framework for biopharmaceutical patents, emphasizing novelty, inventive step, and industrial application. Patentability hinges on exact compliance with statutory criteria, enforceability depends on maintaining validity through diligent prosecution, and claim scope is shaped by technical contributions and prior art limitations. Recent jurisprudence aligns French practices with European standards while emphasizing specific considerations for biotech inventions.

---

What Are the Requirements for Patentability of Biopharmaceuticals in France?

France follows the European Patent Convention (EPC) and its national patent laws, which specify three main criteria:

• Novelty: The invention must not be disclosed publicly before filing.
• Inventive Step: It must differ sufficiently from prior art, showing non-obvious technical advancement.
• Industrial Applicability: The invention should be capable of manufacturing or use in industry.

Biotech inventions, including biopharmaceuticals, are patentable if they meet these criteria. France explicitly allows patent protection for:

• New peptides, proteins, or antibodies.
• Methods of producing biological products, provided the methods are sufficiently disclosed.
• Uses, but only if they are new, inventive, and specific.

Exclusions include discoveries, mere presentations of information, and biological material as such, unless they are isolated, purified, or have a specific technical effect. Specifically, the European legislations and French law exclude from patentability: discoveries of natural substances, methods of treatment, and new uses of known substances unless they involve inventive steps and specific applications.

---

How Does French Patent Law Address Enforceability of Biopharmaceutical Patents?

Enforceability depends on maintaining patent validity through:

• Proper Patent Drafting: Clear, detailed claims that delineate the inventive features.
• Timely Payment of Fees: Annual renewal fees ensure ongoing rights.
• Defending Against Invalidity Arguments: Challenges often cite lack of novelty, inventive step, or exceptions (e.g., discoveries or methods of treatment).

In France, strong enforceability involves:

• Challenging Invalidity: Defendants may argue claims lack inventive step or are directed toward non-patentable subject matter.
• Litigation and Opposition Procedures: The French courts, along with the European Patent Office (EPO), handle patent disputes. Oppositions are filed within nine months of patent grant at the EPO, focusing on prior art and legal compliance.
• Judicial Validation: French courts will assess patent scope within infringement litigation to determine whether alleged infringing activity falls under the patent claims.

Enforceability can be compromised through terminal invalidity procedures or amendments during opposition, necessitating precise claim scope and detailed description.

---

What Influences the Scope of Patent Claims for Biopharmaceuticals in France?

The scope of claims defines the breadth of protection and is constructed based on:

• Amendments in Patent Application: Claims must be supported by the description and be clear, concise, and supported in the original disclosure.
• Claim Drafting Strategy: Broader claims often cover multiple embodiments but risk invalidation if too vague or unsupported. Narrow claims provide stronger defensibility against prior art.

French patent practice favors:

• Dependent Claims: Specify particular embodiments or limitations, reinforcing broad independent claims.
• Functional Claims: Define the biopharmaceutical product or process by its technical effect, which helps in establishing scope.
• Multiple Claim Sets: Covering core inventive features and specific variants, enabling flexible enforcement.

French courts interpret claims by considering the entire patent and description, ensuring claims are not interpreted in isolation. Excessively broad claims may be challenged during opposition or invalidity proceedings, especially if they lack specific technical features.

---

How Does France Handle Patentability and Claims for Biological Material?

French law aligned with EPC allows patenting isolated, purified, or modified biological material if:

• The material possesses a specific technical property.
• It is sufficiently disclosed for the skilled person to reproduce it.
• It involves inventive features distinguishing it from naturally occurring counterparts.

Claims for biological material are often limited to:

• Specific sequences (DNA, proteins).
• Variants with technical modifications or improvements.

Due to the challenges of claiming naturally occurring substances, patent protection typically extends to isolated and modified forms with demonstrated technical values.

---

What Are Common Pitfalls in French Biopharmaceutical Patent Applications?

• Overly Broad Claims: Lack of support or clarity can lead to invalidation.
• Failure to Disclose Adequately: Insufficient description limits enforceability and scope.
• Claiming Natural Substances: Natural products as such are excluded unless isolated or produced by technical means.
• Missing Inventive Step: Claims relying solely on known methods or naturally occurring substances face rejection.

Pre-filing patent searches and conforming claims to prior art increase the chance of obtaining broad, enforceable patents.

---

Key Takeaways

• French law permits patent protection for biopharmaceutical inventions, subject to novelty, inventive step, and industrial application.
• Enforceability relies on robust drafting, correct claim scope, and diligent maintenance.
• The scope of claims is influenced by how well the invention is described and supported in the patent application.
• Biological materials require specific, technical modifications to be patentable.
• Common pitfalls include overly broad claims and claims to naturally occurring substances without sufficient inventive features.

---

FAQs

1. Can naturally occurring biological substances be patented in France?
Only if isolated, purified, or modified to demonstrate a specific technical effect. Naturally occurring substances themselves are excluded from patentability.

2. How does French law treat gene patents?
Gene sequences can be patented if isolated and having a new, inventive application or modification. Plain DNA sequences without specific technical modifications are unlikely to be patentable.

3. What is the process for challenging a biopharmaceutical patent's validity in France?
Invalidity claims can be filed during patent opposition (within nine months of grant at the EPO) or via court proceedings based on grounds like lack of novelty, inventive step, or non-patentable subject matter.

4. How broad can claims for biopharmaceuticals in France be?
Claims should balance breadth with support in description. Excessively broad claims risk invalidation; narrowly defined claims provide better enforceability.

5. Are method-of-treatment claims protected in France?
Method-of-treatment claims are generally excluded from patentability unless they involve new, inventive technical steps related to the method itself, not just the medical application.

---

References:

Last updated: February 14, 2026

[1] European Patent Convention, Articles 52-57.
[2] French Intellectual Property Code, sections on patent law.
[3] EPO Guidelines for Examination, Part GIII.
[4] French Court Judgments on biotech patents, 2022-2023.
[5] World Intellectual Property Organization (WIPO), Patentability of Biotechnology Inventions.